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Rapid generation of OPC-like cells from human
pluripotent stem cells for treating spinal cord injury
Dae-Sung Kim1,2,3, Se Jung Jung4, Jae Souk Lee4,5, Bo Young Lim4, Hyun Ah Kim4, Jeong-Eun Yoo4,5,
Dong-Wook Kim4,5 and Joong Woo Leem4
Remyelination via the transplantation of oligodendrocyte precursor cells (OPCs) has been considered as a strategy to improve the
locomotor deﬁcits caused by traumatic spinal cord injury (SCI). To date, enormous efforts have been made to derive OPCs from
human pluripotent stem cells (hPSCs), and signiﬁcant progress in the transplantation of such cells in SCI animal models has
been reported. The current methods generally require a long period of time (42 months) to obtain transplantable OPCs, which
hampers their clinical utility for patients with SCI. Here we demonstrate a rapid and efﬁcient method to differentiate hPSCs into
neural progenitors that retain the features of OPCs (referred to as OPC-like cells). We used cell sorting to select A2B5-positive
cells from hPSC-derived neural rosettes and cultured the selected cells in the presence of signaling cues, including sonic
hedgehog, PDGF and insulin-like growth factor-1. This method robustly generated neural cells positive for platelet-derived growth
factor receptor-α (PDGFRα) and NG2 (~90%) after 4 weeks of differentiation. Behavioral tests revealed that the transplantation
of the OPC-like cells into the spinal cords of rats with contusive SCI at the thoracic level signiﬁcantly improved hindlimb
locomotor function. Electrophysiological assessment revealed enhanced neural conduction through the injury site. Histological
examination showed increased numbers of axon with myelination at the injury site and graft-derived myelin formation with no
evidence of tumor formation. Our method provides a cell source from hPSCs that has the potential to recover motor function
following SCI.
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INTRODUCTION
Spinal cord injury (SCI) induces massive neuronal and glial
cell death along with the loss of axonal connectivity and
demyelination of spared axons, which result in irreversible
deﬁcits in motor and sensory functions at and below the lesion
site.1 Spontaneous recovery in the injured area is limited by the
intrinsic properties of the central nervous system (CNS) and by
an unfavorable environment for axonal regrowth.2 There is
currently no effective therapeutic option to improve functional
outcomes following SCI. Potential repair strategies using cell
replacement have been proposed to restore local neuronal
connectivity and promote the remyelination of denuded axons.
Recently, evidence has been accumulating that the transplanta-
tion of stem cells (for example, bone marrow-derived
mesenchymal stem cells (reviewed in ref. 3), fetal neural stem
cells (NSCs; reviewed in ref. 4), ependymal stem/progenitor
cells,5 and neural precursors (NPs) derived from pluripotent
stem cells (PSCs)6,7) could promote locomotor recovery. Such
transplantation can be considered a promising strategy for the
treatment of SCI. In particular, NPs derived from PSCs have
been reported to improve locomotor function in injured
animals through the partial recovery of impaired neuronal
circuits or the remyelination of spared axons (reviewed in ref. 8).
When the spinal cord is injured, the loss of oligodendrocytes
(ODs) and the consequent demyelination of axons contribute
to the impairment of locomotor function9 and can therefore be
considered therapeutic targets for cell replacement after SCI.
Several reports have provided convincing evidence that the
transplantation of OD precursor cells (OPCs) derived from
human embryonic stem cells (hESCs) into the spinal cords of
injured animals leads to axonal remyelination and functional
recovery.7,10–14 Recently, a clinical trial using hESC-derived
OPCs to treat SCI was attempted.15 Despite recent progress in
the transplantation of hESC-derived OPCs, several critical
issues remain to be solved before the method can be translated
into clinical treatments for SCI. First, the current protocols
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for the differentiation of OPCs/ODs from hESCs consist of
multiple steps and require long periods of time (at least
2 months) to derive OPCs with the potential to generate
myelin sheaths after transplantation,16 increasing concerns
about batch-to-batch variation in differentiation efﬁciency
and the risk of contamination. Second, the occurrence of
non-neural tissues within the grafts has been problematic,
likely caused by the non-neural derivatives that can be
generated along with OPCs during differentiation of hESCs.
The optimal timing of cell transplantation is another issue in
debate for treating SCI patients. In general, the acute phase, a
stage within a few days of SCI, is generally considered not
optimal for transplantation because of massive immune
responses and tissue necrosis occurring. In contrast, after
weeks or even months, in the chronic phase, a glial scar and
inhibitory milieu that forms to protect spared tissue prohibit
regeneration; thus cell transplantation may be inefﬁcient. For
these reasons, many studies using animal models have
attempted to utilize the subacute phase, one to two weeks
after injury, to maximize the efﬁcacy of cell transplantation
because it is a stage when acute immune responses have
subsided and an inhibitory environment has not yet been
established.8,17,18 Nevertheless, there is still no consensus on the
optimal timing for cell transplantation in human patients;
thus, further studies are required. These issues are considered
major hurdles for the successful treatment of SCI by the
transplantation of hESC-derived OPCs.
In an effort to overcome those technical challenges,
we sought to obtain highly pure populations of NPs from
hPSCs that retain the features of OPCs. To that end, cell
sorting using the monoclonal antibody A2B5, which recognizes
GT3 ganglioside and its O-acetylated derivatives19 (hereafter
referred to as A2B5), not only enhanced the homogeneity of
the derived neural cell population but also eliminated cells of
other lineages as well as undifferentiated remnants from the
hESC-derived neural progenies. The subsequent culture of the
cells in the presence of signaling molecules favorable for
OPC differentiation generated a relatively pure population
of cells exhibiting OPC-like phenotypes within 4 weeks
following differentiation from hPSCs. When the cells were
transplanted into a subacute rat model of contusive SCI,
signiﬁcant locomotor recovery was observed in the hindlimbs.
Immunohistochemical analyses showed that the grafts survived
well in the injected site, where they differentiated into
cells exhibiting the characteristic of ODs and did not
form non-neural tissues or teratomas. Our simple and
straight-forward approach may provide a clinically applicable
cell source for treating motor dysfunction elicited by SCI.
MATERIALS AND METHODS
Cell culture and generation of OPC-like cells
hESCs (WA09, WiCell, Madison, WI, USA) and hiPSCs (MSC-iPSC,20
a gift from Dr Daley, Harvard University) were cultured and
differentiated into NPs following a method described elsewhere.21,22
Brieﬂy, undifferentiated hPSCs were cultured with mitotically inacti-
vated feeder cells (STO; ATCC, Manassas, VA, USA) in DMEM/F12
medium supplemented with 20% Knock-out Serum Replacement
(KSR; Invitrogen, Carlsbad, CA, USA), 1 × non-essential amino acids
(Invitrogen), 0.1 mM β-mercaptoethanol (Sigma, St Louis, MO, USA),
and 4 ng ml− 1 basic ﬁbroblast growth factor (bFGF; Peprotech, Rocky
Hill, NJ, USA). To induce neural differentiation, hPSC colonies were
lifted and cultured as embryoid bodies (EBs) in the presence of 5 μM
dorsomorphin (Sigma) and 5 μM SB431542 (Calbiochem, San Diego,
CA, USA) for 4 days and then cultivated on a Matrigel-coated
(Corning, Corning, NY, USA) culture dish in 1× N2-containing
(Invitrogen) medium supplemented with 20 ng ml− 1 bFGF for an
additional 5–7 days. Once neural rosettes appeared in the centers of
attached EB colonies, they were mechanically isolated with a ﬁnely
pulled Pasteur pipette and then passed onto a new Matrigel-coated
culture dish after gentle trituration. The cells were expanded in N2B27
medium (composed of DMEM/F12 medium, 1× N2 and 1× B27
(Invitrogen)) supplemented with 20 ng ml− 1 bFGF and 20 ng ml− 1
epidermal growth factor (EGF; Peprotech) for another week.
A2B5-positive cells were isolated using Anti-A2B5-MicroBeads
(Miltenyi Biotec, Bergisch Gladbach, Germany) from the expanded
neural rosette cells according to the manufacturer’s instructions. To
induce cells with OPC-like phenotypes, the isolated A2B5-positive cells
were seeded on a ﬁbronectin-coated (Corning) culture dish at a
density of ~ 2–3× 105 cells per cm2 and cultured in N2B27 medium
supplemented with 10 ng ml− 1 PDGF-AA (Peprotech), 10 ng ml− 1
insulin-like growth factor-1, 100 ng ml− 1 Sonic hedgehog (SHH)
(R&D Systems, McKinley Place, MN, USA), 5 μM forskolin (Sigma)
and 60 μg ml− 1 N-acetyl cysteine (NAC; Sigma) for another 7–10 days.
The cells could then be cryopreserved in cryoprotectant medium
(N2B27 medium: KSR: dimethyl sulfoxide= 4: 5: 1) or expanded by
enzymatic passaging (Accutase; Millipore, Temecular, CA, USA).
Analyses by immunoﬂuorescent staining, ﬂow cytometry
and reverse transcription polymerase chain reaction
Cells were ﬁxed in 4% paraformaldehyde/PBS solution for 30 min,
permeabilized with 0.1% Triton X-100/PBS (only for intracellular
markers) for 10 min, blocked with 5% normal donkey serum for 1 h
at room temperature, and then incubated with primary antibodies at
4 °C overnight. The primary antibodies used in our study were as
follows: SOX1 (1:200, Millipore), PAX6 (1:200, DSHB, Iowa City, IA,
USA), Nestin (1:1000, Millipore), A2B5 (1:200, Millipore), PDGFRα
(1:100, Santa Cruz Biotechnology, Dallas, TX, USA or 1:100,
Millipore), NG2 (1:200, Millipore), and Musashi1 (1:100, R&D
Systems). After the primary antibody incubation, appropriate
ﬂuorescent secondary antibodies (Alexa-Fluor-488 or -594, Molecular
Probes, Eugene, OR, USA) were used for visualization. The cells were
treated with 4′,6-diamidino-2-phenylindole (DAPI; Vectashield,
Vector Laboratories, Burlingame, CA, USA) for 5 min during the
staining procedure to visualize the nuclei. Cell images were captured
with an Olympus IX71 microscope (Olympus, Shinjuku, Tokyo,
Japan) and a DP71 digital camera (Olympus) and analyzed using
Image-Pro Plus ver5.1 (Media Cybernetics, Rockville, MD, USA). For
ﬂow cytometry analysis, the cells were dissociated by incubation in
Accutase (Millipore) for 5 min at 37 °C and then blocked in 2%
bovine serum albumin–PBS solution for 5 min at 4 °C. The cells were
bound with primary antibodies for 15 min at 4 °C. After tagging
with ﬂuorescence-conjugated secondary antibody (Alexa-Flure-488)
followed by extensive washing, the cells were analyzed using FACScan
(BD Bioscience, Franklin Lakes, NJ, USA) and the Cell Quest Pro
program (BD Bioscience). For reverse transcription polymerase chain
reaction (RT-PCR) analysis, total RNAs were extracted using a TRIzol
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total RNA puriﬁcation kit (Invitrogen). Then, 1 μg of the extracted
RNA was reverse transcribed using an iScript cDNA synthesis kit
(Bio-Rad, Hercules, CA, USA). The cDNAs of speciﬁc genes were
ampliﬁed using PowerUP SYBR master mix (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) in a Step One-plus real-time PCR machine
(Thermo Fisher Scientiﬁc). The primer sequences and reaction
conditions for the ampliﬁcation of the speciﬁc genes are described
in Supplementary Table 1.
Spinal cord injury and cell transplantation
Adult male rats (Sprague-Dawley, 200–225 g, Harlan Laboratories,
Seoul, Korea) were anesthetized under masked-inhalation anesthesia
(enﬂurane: induction 3%; maintenance 2%), and a small longitudinal
skin incision and laminectomy were performed at the T9 vertebral
level. The exposed dorsal surface of the spinal cord was subjected to a
weight-drop impact, which was carried out by dropping a 10 g weight
rod from a 25 mm height onto the cord surface using the NYU
weight-drop impactor. The consistency of SCI among the animals was
guaranteed by monitoring the contusion impact velocity and com-
pression rate. The animals were warmed by radiant heat lamps during
recovery from anesthesia. Manual bladder compression was performed
2–3 times per day to eliminate as much urine as possible until the
animals were urinating independently. Animals that did not recover
bladder function were excluded from further analysis.
One week after SCI, the rats received OPC-like cell transplantation
or vehicle injection. With the rats under masked-inhalation anesthesia
(enﬂurane: induction 3%; maintenance 2%), the spinal cord was
re-exposed at the SCI level, and a tiny hole was opened in the dura
mater over the epicenter of the injury site. The ﬁne tip of a glass
capillary (850 μm in O.D. with 100 μm tip diameter) ﬁlled with
OPC-like cells (1× 105 cells per 5 μl) or PBS vehicle and connected to
thin rubber tubing was inserted through the dura hole 1 mm from the
cord surface at the injury epicenter. The OPC-like cells or PBS vehicle
were administered into the spinal cord over a period of 30 s by
blowing on the open end of the rubber tube. The capillary was left in
place for 1 min and then slowly withdrawn to avoid any outﬂow of the
cell suspension. The incised skin was sutured, and the animal was
returned to its cage. For immune suppression, the animals received
cyclosporine-A (10 mg kg− 1, i.p.) every day beginning on the ﬁrst day
prior to transplantation and continuing until the second week after
transplantation. All surgeries and experiments were done with the
approval of the Institutional Animal Care and Use Committee of
Yonsei University College of Medicine, Seoul, Korea.
Behavioral assessment
The improvement of mobility for rats that underwent SCI followed by
either OPC-like transplantation (n= 11) or PBS vehicle injection
(n= 9) was examined. The animals were trained preoperatively to test
locomotor functions by means of an open-ﬁeld locomotor rating
scale, as described by Basso, Beattie and Bresnahan (BBB), which
ranged from complete paralysis (score= 0) to normal locomotion
(score= 21).23 The rats were gently adapted to the open ﬁeld, which
was a molded-plastic circular enclosure with a smooth, non-slip ﬂoor
(90 cm diameter, 30 cm wall height). Once a rat walked continuously
in the open ﬁeld, three blinded examiners conducted a 5-min,
preoperative testing session using the BBB locomotor rating scale.
Postoperative testing was performed on days 1, 4 and 7 after SCI and
then weekly for 8 weeks after transplantation. The BBB scores
collected from both hindlimbs were averaged for analysis.
Electrophysiological assessment
Myoelectric motor-evoked potentials (mMEPs) were recorded from
the gastrocnemius muscle of SCI rats that received OPC-like
transplantation (n= 16) or PBS vehicle injection (n= 9) to monitor
the improvement of impulse conduction in the motor system.
The techniques used for the stimulation, recording and electrode
implantation are described elsewhere.24,25 Brieﬂy, the rat was
anesthetized with enﬂurane, and the head was ﬁxed in a stereotaxic
frame. A midline incision of the head skin was then made to expose
the skull. Two holes (each 2 mm in diameter) were drilled to implant
stainless-steel screws on the right side; one was positioned over the
somatomotor cortex (2 mm posterior to the bregma, 2 mm lateral to
the midline), and the other was positioned over the olfactory bulb
(6.5 mm anterior to the bregma, 1 mm lateral to the midline). A screw
(2 mm in diameter, 10 mm in length) was implanted and turned three
times into the skull hole so that the ﬂattened bottom end of the screw
touched the cortical meninges. The exposed surface of the skull was
covered with cyanoacrylic glue and dental cement to ﬁx the screws.
The skin was then sutured, leaving the screw heads exposed for use as
active and reference stimulating electrodes.
The mMEPs were recorded immediately before and after SCI and
on weeks 4 and 8 post transplantation. With the rats under enﬂurane
anesthesia, the mMEPs were recorded using needle electrodes that
were inserted trans-cutaneously into the left gastrocnemius muscle,
with the active electrode placed into the muscle belly and the reference
electrode placed near the distal tendon. To elicit mMEPs, a single
square-pulse electrical stimulus (0.2 ms duration, 6 mA intensity, 2 Hz
interval) was delivered through the screw electrodes by a stimulus
isolator (SI-1850, World Precision Instruments, New Haven, CT,
USA). Analog mMEP signals were ampliﬁed (500 000× ), bandpass
ﬁltered (100–2000 Hz), and fed into a computer through a data
acquisition unit (CED 1401 plus, Cambridge Electronic Design,
Cambridge, UK). Ten mMEP traces with a sweep length of 50 ms
were averaged before saving.
The area under the mMEP wave was measured using a software
program (ImageJ 1.45, NIH, Bethesda, MD, USA) to indicate the
number of axons involved in the impulse conduction through the
corticospinal tracts. The onset latency of the mMEP wave was
measured as the time difference between the stimulus-artifact point
and the wave-initiation point. The post-transplantation area and
latency values were expressed as percentages of the pre-SCI values.
Quantiﬁcation of myelinated axons in the ventrolateral white
matter
We used toluidine blue staining to examine the extent of improvement
in the myelination of the spinal motor axons after SCI in OPC-like
cell-transplanted (n= 5) and PBS vehicle-treated (n= 5) rats that had
completed the 9-week behavioral test and in sham-operated rats
(n= 3) that underwent the same surgical procedures but without
SCI and cell transplantation or PBS injection. The animals were
anesthetized with urethane (1.5 g kg− 1, i.p.) and perfused with
0.1 M phosphate buffer (PB) and 2% paraformaldehyde plus 2%
glutaraldehyde in 0.1 M PB. The spinal cord was dissected to
collect three slices (each 1 mm in thickness) at the lesion epicenter
and at sites 5 mm rostral and 5 mm caudal to the lesion epicenter,
respectively. The spinal cord slices were incubated in the same ﬁxatives
overnight at 4 °C and then washed in 0.1 M PB. For semi-thin sections,
the cord slices were post ﬁxed with 1% OsO4 dissolved in 0.1 M PB for
2 h, dehydrated in ascending gradual ethanol series (50–100%),
and inﬁltrated with propylene oxide. The cord slices were embedded
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using a Poly/Bed 812 kit (Polysciences, Warrington, PA, USA)
and polymerized by ultraviolet irradiation at 60 °C in an electron-
microscope oven (TD-700, DOSAKA EM, Kyoto, Japan) for 24 h.
Using an ultra-microtome (Leica Ultracut UCT, Wetzlar, Germany),
the cord slices were cut coronally into 1-μm-thick semi-thin sections.
Every 100th section was collected and stained with toluidine blue to
visualize myelinated axons under light microscopy (Powershot A620,
Canon, Tokyo, Japan).
To quantify the myelination of the spinal motor axons, the
myelinated axons in the ventrolateral white matter of the spinal cord
were sampled for examination. The crossed central lines of a gridded
microscope eyepiece were initially adjusted over the semi-thin sections
at × 40 magniﬁcation by rotating the eyepiece so that one line ran
vertically between the outermost center points of the dorsal and ventral
columns, the other line ran horizontally across lateral columns on both
sides of the spinal cord, and the line–line intersection was positioned
on the central canal. The region of ventrolateral white matter was then
located at × 100 magniﬁcation by adjusting the microscope stage to
move the intersection point of the grid lines in the radial direction
from the central canal to the outermost limit of the spinal cord. When
the center of the ﬁeld of view reached the area near the outermost
boundary of the ventrolateral white matter, the magniﬁcation was
increased to ×400, and an image was captured by a digital camera. The
digital images were processed with Photoshop (Adobe, San Jose, CA,
USA) and overlaid with a square frame (50× 50 μm2). The myelinated
axons in 2500 μm2 areas, which were sampled from the ventrolateral
white matter on both sides of the spinal cord in each of 10 semi-thin
sections collected from three different cord levels of each rat, were
counted and averaged for analysis. The axon counts, behavioral, and
mMEP assessments were performed by investigators who were blind to
the surgery and treatment that the animals had received.
Immunohistochemistry
To evaluate the characteristics of the transplanted cells in vivo,
we performed immunohistochemical staining using three OPC-like
Figure 1 OPC-like cells differentiated from human pluripotent stem cells. (a) A2B5-immunoreactive cells in the neural rosette stage on day
10 of differentiation. (b, c) Flow cytometry analysis reveals enrichment of the A2B5-positive population (a dark blue peak before
cell sorting vs a light blue peak after cell sorting). (d, e) Bright-ﬁeld images of OPC-like cells cultured in PSI medium. (f) Culture in
PSI media upregulated expression of genes involved in OD speciﬁcation. (g–i) Immunocytochemical analysis shows a high yield of
PDGFRα-positive and NG2-positive cells in the OPC-like cell culture. Scale bars represent 25 μm. Error bars indicate s.e.m. *Po0.05,
Student’s t-test.
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cell-transplanted SCI rats that had completed the 9-week behavioral
test. The animals were anesthetized with urethane (1.5 g kg− 1, i.p.)
and perfused with PBS and 4% paraformaldehyde in PBS. The full
length of the spinal cord from 6 mm rostral of the lesion epicenter to
6 mm caudal of the lesion epicenter was dissected and post ﬁxed for
4–6 h with 4% paraformaldehyde, immersed overnight in 30% sucrose
in 0.1 M PBS, and embedded in an OCT compound (Tissue-Tek,
Torrance, CA, USA). Some of the ﬁxed cord segments were cut into
10 μm sagittal sections, and others were cut into 10 μm coronal
sections using the cryostat. Every tenth cord section was collected,
mounted onto gelatin-coated slides, and stored at − 70 °C before
immunostaining was performed.
Immunohistochemistry was conducted with sagittal sections to
identify oligodendrocytes that had differentiated from the transplanted
OPC-like cells and with coronal sections to identify other graft-derived
cells. The cord sections were rinsed with PBS three times, blocked
overnight with 3% bovine serum albumin in PBS containing 0.3%
Triton X-100, and incubated with primary antibodies for 1 day at 4 °C
in the presence of a blocking solution. The primary antibodies used for
the sagittal sections were mouse anti-human nuclei (HNA) mono-
clonal antibody (1:100, Millipore) and rabbit anti-myelin basic protein
(MBP; 1:200, Millipore). The primary antibodies used for the coronal
sections were HNA, rabbit anti-microtubule associated protein 2
(MAP2; 1:100, Millipore), rabbit anti-glial ﬁbrillary acidic protein
(GFAP; 1:500, Millipore), and rabbit anti-ki67 (1:150, Leica,
Richmond, IL, USA). The cord sections were then washed, and
species-speciﬁc secondary antibodies (anti-rat Alexa Fluor 488 or
anti-mouse Alexa Fluor 594, 1:200; Molecular Probes) were applied
for 1 h at room temperature. The slides were then cover-slipped with
Vectashield (Vector Laboratories) containing the nuclear counter-stain
DAPI and observed under a ﬂuorescence microscope (BX50,
Olympus) or confocal microscope (FV10-ASW, Olympus).
Statistical analysis
The results from the behavioral tests and mMEP recordings were
analyzed with a two-way repeated measures analysis of variance
(ANOVA). The data from the axon counts were analyzed with
a two-way ANOVA. When the ANOVAs identiﬁed signiﬁcant
differences, pair-wise comparisons between mean values were
performed using post hoc Tukey’s tests. Statistical signiﬁcance of FACS
analysis (Figure 1c) was examined by Student’s t-test with three
independent experiments. Signiﬁcance was set at Po0.05. The data are
presented as the mean± s.e.m.
RESULTS
Generation of OPC-like cells from hESCs
We previously showed that NPs could be efﬁciently generated
from hESCs via the simultaneous inhibition of BMP and
Activin/Nodal signals.21 EB culture in the presence of two
inhibitors (that is, 5 μM dorsomorphin and 5 μM SB431542)
and subsequent adherent culture in neural-inducing medium
generated robust clumps of neural cells, which we refer to as
neural rosettes, from hESCs within a week (Supplementary
Figure 1A–C). We mechanically dissected the radially arranged,
columnar-shaped cells in the neural rosettes under a dissection
microscope and passed them onto a Matrigel-coated culture
dish for expansion. Consistent with our previous ﬁnding,26
immunocyto-chemical analysis conﬁrmed that the cells at
that stage strongly expressed several neural markers, including
SOX1, PAX6, Nestin and Musashi-1 (Supplementary Figure 1D
and E). RT-PCR analysis of the time-course of gene expression
revealed that the expression of the neural markers was induced
and sustained over the period of differentiation, whereas the
expression of OCT4, a marker of pluripotency, was reduced
as the differentiation proceeded (Supplementary Figure 1F).
When we examined the expression of A2B5, a substantial
proportion (~70%) of the cells were positive (Figure 1a and c),
but the proportion of positive cells did not signiﬁcantly
increase even after further prolonged expansion in medium
supplemented with EGF, which is used to expand NPs for OPC
differentiation27 (data not shown). Because A2B5-expressing
cells are the ﬁrst population to emerge in OD differentiation,
we decided to enrich the A2B5-positive cells and expose them
to the culture conditions favorable for OPCs, expecting that
such an approach might curtail the period required for
expansion and facilitate the commitment of the cells toward
OPCs. To enrich the A2B5-positive population, we took
advantage of cell sorting using magnetic beads conjugated with
an A2B5 antibody, which is relatively benign to the cells and
easily scalable.28 After expanding cells from the neural rosettes,
we were able to use the cell sorting to enrich the A2B5-positive
cells up to 95% of the total cell population and greatly
reduce the variation among the cells (Figure 1b and c). We
obtained comparable results using another hiPSC line as well
(Supplementary Figure 2).
To further differentiate the A2B5-positive cells into OPCs,
we cultured them in medium supplemented with 10 ng ml− 1
PDGF-AA, 100 ngml− 1 SHH and 10 ngml− 1 IGF-1 (hereafter
referred to as PSI medium), all well-known factors for the
induction and maintenance of OPCs.29–31 After 7–10 days of
additional culture in the PSI medium, most of the cells
displayed an oval-shaped cell body with two or three long
processes, the typical morphology of pre-OPCs32 (Figure 1d
and e). RT-PCR analysis revealed that the cells cultured in
the PSI medium upregulated their expression of several
genes involved in OD survival and speciﬁcation,33,34 including
SOX8/10, members of the SOX (SRY-related HMG-box)
family of transcription factors, and OLIG1/2, basic
helix–loop–helix transcription factors, which are essential for
OD development35 (Figure 1f). When we further examined
the expression of OPC markers by immunocytochemistry, the
great majority of the cells were labeled with anti-PDGFRα and
NG2 antibodies (91.2± 3.8% and 91.7± 3.7%, respectively;
Figure 1g–i). Because the cells exhibited immunoreactivity
against multiple markers, including A2B5, PDGFRα and
NG2, as well as enhanced expression of OPC markers
as determined by RT-PCR, we referred to these cells as
‘OPC-like’ cells.
In addition to enriching the cells of interest, the cell sorting
should also exclude unwanted cells, including undifferentiated
remnants from the culture which might cause undesirable
tissues to form after transplantation.36 As expected,
multiple immunocytochemical examinations showed that cells
expressing OCT4 and/or NANOG were absent from the culture
after the A2B5-mediated cell sorting (Supplementary Figure 3).
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Together with the RT-PCR data showing the lack of OCT4
transcripts (Supplementary Figure 1F), the results showed that
the populations obtained by the cell sorting had a more reliable
phenotype and were thus more compatible with the purpose of
transplantation and less likely to lead to teratoma formation.
Improvement of hindlimb locomotor recovery in SCI rats
after OPC-like cell transplantation
To test the potential of OPC-like cells as a therapy to treat SCI,
we transplanted the cells into the lesion site in SCI rats and
assessed locomotor function using the BBB scale. The rats
completely lost their hindlimb mobility (BBB score= 0)
bilaterally after SCI (Figure 2a). The SCI rats progressively
recovered some locomotor activity, however, with some move-
ment of the hip, knee and ankle joints (BBB score= 5–7);
during the ﬁrst week post SCI, after which they received
transplantation of OPC-like cells (n= 11) or PBS vehicle
(n= 9) into the lesion site. The SCI rats that received the
PBS injection recovered further, up to a BBB score of
~ 9 through 3 weeks post PBS treatment, showing weight-
supported stepping using the dorsum, but not the sole, of the
foot. However, compared with those of the PBS-treated control
rats, the BBB scores of the rats that received the OPC-like cell
transplants signiﬁcantly increased from 3 weeks post trans-
plantation to the last day of behavioral testing (Po0.05),
indicating that the OPC-like cell transplantation signiﬁcantly
improved locomotor recovery in the SCI rats. The improved
locomotor function included weight-supported stepping using
the sole of the foot and locomotor activity with coordinated
forelimb and hindlimb movement.
To assess the functional integrity of the descending axons
from the motor cortex directly or indirectly through the
brainstem to the spinal cord, we recorded mMEPs from the
contralateral gastrocnemius muscle in SCI rats given OPC-like
transplants (n= 16) or PBS injection (n= 9). The mMEPs,
the conduction of which was blocked by the SCI, began to
reappear 4 weeks after transplantation (Figure 2b); however,
no signiﬁcant differences in the area under the wave form or
the onset latency between the two groups were observed at
4 weeks post transplantation. Eight weeks after transplantation,
Figure 2 Recovery of hindlimb locomotor function and mMEPs in SCI rats after OPC-like cell transplantation. (a) The average BBB score of
both hindlimbs for each rat was assessed in two groups: rats receiving cell transplants or PBS, respectively, 1 week after SCI. The
functional test shows a signiﬁcant improvement in the SCI rats treated with cell transplants compared with those treated with PBS,
beginning at least 3 weeks after cell transplantation. (b) Representative waveforms of mMEPs in rats that underwent SCI followed by
treatment with either cell transplantation or PBS immediately before and after SCI and at weeks 4 and 8 post transplantation. (c) The
onset latency of mMEP and the area under the mMEP wave were evaluated with respect to the pre-SCI value. Eight weeks post
transplantation, the cell-transplanted SCI rats displayed a signiﬁcant decrease in the onset latency and a signiﬁcant increase in the area
under the mMEP wave compared with the PBS-treated controls. No signiﬁcant difference in these two measures between the groups was
observed 4 weeks post transplantation. Error bars indicate s.e.m. *Po0.05.
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however, the mMEPs in the rats that underwent OPC-like
transplantation showed larger amplitudes and faster conduc-
tion velocities than those in the rats that received the PBS
injections. The onset latency and area under the mMEP wave
were quantiﬁed as indicators of recovery of the functional
integrity of the descending axons from the somatomotor cortex
(Figure 2c). Eight weeks after transplantation, the rats that
received the OPC-like transplants demonstrated a signiﬁcant
decrease in the mMEP onset latency and a signiﬁcant increase
in the area under the mMEP wave form compared with the
rats that received the PBS injections (486.3± 41.9% vs
335.8± 18.1%, Po0.05;13.7± 1.8% vs 41.7± 9.6%, Po0.05;
respectively).
Increased numbers of myelinated axons in the ventrolateral
white matter after OPC-like cell transplantation
To assess the anatomical substrate for the functional improve-
ment of the descending axons from the somatomotor cortex
after OPC-like cell transplantation, we investigated whether
OPC-like transplantation increased the number of myelinated
axons in the ventrolateral white matter of the spinal cord.
After toluidine blue staining to visualize the myelinated axons,
we counted the numbers of myelinated axons in squares
(50× 50 μm2) placed on the ventolateral white matter in
coronal sections collected at three different levels of the
spinal cord: at the lesion epicenter, 5 mm rostral to the lesion
epicenter, and 5mm caudal to the lesion epicenter (Figure 3a).
As shown in Figure 3b, myelin loss was apparent in the rats
that received the PBS injections (middle lane). Conversely, the
rats that received the OPC-like transplants had improved tissue
integrity and increased numbers of myelinated axons around
the injury site compared with the PBS-treated rats (Figure 3b,
right). The SCI rats given OPC-like transplants often displayed
thinner myelin sheaths compared with the sham-operated
animals (unaffected myelin), which were presumably evidence
of remyelinated axons37 or spared axons protected from
massive demyelination38 (Figure 3b, III). Cell-count analysis
of the myelinated axons (Figure 3c) revealed that the rats that
received the OPC-like transplants had signiﬁcantly more
myelinated axons at all cord levels compared with those that
received the PBS injections (95.7± 5.8 vs 73.8± 2.8 at 5 mm
rostral to the lesion epicenter, 80.4± 10.4 vs 55.2± 4.2 at the
lesion epicenter, and 91.5± 3.8 vs 73.9± 2.9 at 5 mm caudal to
the lesion epicenter; Po0.05 for each comparison); although
they had fewer myelinated axons than the sham-operated
rats (116.5± 7.5, 114.2± 2.3 and 105.7± 2.3 at the three
cord levels, respectively; Po0.05 for each comparison), which
explains the partial recovery of locomotor function by cell
transplantation. Taken together, our data strongly suggest that
the transplantation of OPC-like cells increased the number of
myelinated axons, supporting the potential of OPC-like cells to
serve as a source for treating SCI-induced motor deﬁcits.
Fate of the transplants at 8 weeks after transplantation
Next, we examined the fate of the OPC-like cell grafts in
the injured spinal cords. Eight weeks post transplantation, the
grafts showed strong survival and extended migration within
the injured spinal cords, as shown by immunostaining with
HNA (Figure 4a). Many HNA-positive cells occupied the lesion
cavity induced by the SCI and migrated both rostrally and
caudally to distances of at least 5 mm from the transplant site,
with the vast majority of HNA-positive cells remaining near the
transplanted area. As evidenced by triple labeling with DAPI,
anti-HNA and anti-MBP antibodies (Figure 4b), a considerable
number of HNA-positive cells was located adjacent to the areas
of MBP immunoreactivity throughout the transplanted cells,
suggesting the presence of myelinating cells derived from the
transplanted OPC-like cells. HNA/GFAP double-positive cells
and HNA/MAP2 double-positive cells were frequently observed
throughout the injection area (Figure 4c and d, o20% of
surviving transplanted cells in both cases), which suggest that
the OPC-like cells retained tripotency, likely because they
were not fully committed toward the OD lineage. In addition,
Ki67-positive cells were occasionally detected among the
transplanted cells (Figure 4e), indicating that a few transplanted
cells did not fully differentiate into the mature cells even
8 weeks after transplantation. We did not, however, ﬁnd
evidence of formation of non-neural tissues, neoplastic cell
masses or teratomas. Collectively, our evidence shows that
although the OPC-like cells were not fully committed to
exclusively generate ODs, they had the potential to generate
cells that were able either to create myelin sheaths on axons or
to protect axons from massive demyelination after transplanta-
tion into the spinal cords of rats with contusion injuries.
DISCUSSION
We showed that the enrichment of A2B5-positive cells from
hPSC-derived neural rosette cells, and exposure of the enriched
cells to signaling cues implicated in oligodendrogenesis,
robustly generated OPC-like cells expressing PDGFRα and
NG2 within a short time period (~4 weeks). After transplanta-
tion into traumatically injured rat spinal cords, the OPC-like
cells were well integrated into the injured tissue and were able
to differentiate MBP-positive cells. Our in vivo evidence
demonstrated that (1) the number of myelinated axons in
the injured spinal cords that received OPC-like cells was
signiﬁcantly increased compared with that in control spinal
cords; (2) the neural conduction evoked by electric stimulation
through the injury site was enhanced by the OPC-like
transplants; and (3) distinctive MBP immunoreactivity was
frequently observed contiguous with HNA immunoreactivity in
the cell-injection site. Collectively, our results demonstrate a
fast and efﬁcient differentiation system for hPSCs that can
provide a cell source with the potential to improve motor
dysfunction caused by SCI.
As highlighted by several studies,39,40 one of the challenges
of OD differentiation from hPSCs is that the procedure is
time-consuming and requires multiple steps. One can assume
that when long periods of time are required to obtain cells of
interest, the ﬁnal cell populations will have a large amount
of variation in yield and an increased risk of contamination
(for example, by microorganisms or unwanted cell lineages).
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Accordingly, such time-consuming approaches might also be
expected to come with higher costs and labor requirements for
quality control, which could be a signiﬁcant factor in delaying
their transition to clinical applications. In an attempt to resolve
those limitations, the goal of the present study was the
acquisition of transplantable OPC-like populations in a way
that is signiﬁcantly faster than previous methods. Our strategy
was to enrich NPC populations with cells that had a fate
restricted to the OD lineage by sorting for A2B5-positive cells.
The monoclonal antibody A2B5 was originally characterized
as detecting a speciﬁc glycoprotein expressed on neurons,41
which was subsequently shown to be expressed on glial-lineage
cells (that is, type-2 astrocytes and OPCs42). Taking advantage
of that speciﬁcity, previous studies utilized A2B5 immuno-
reactivity to identify and/or enrich a cell source appropriate
for transplantation to repair demyelinated lesions from
either rodent fetal neural tissue43 or mESC-derived NPs.44,45
Subpopulations of A2B5-positive cells (negative for polysialic
acid-neural cell adhesion molecule) isolated from fetal and
adult human brain tissues have been transplanted and have
successfully generated myelin sheaths on axons in animal
brains with congenital defects in myelination.46 Those results
provided a reasonable clue for using A2B5 to enrich hPSC
populations with cells that are committed toward OD differ-
entiation. It has been generally believed, however, that OPCs
could not be identiﬁed by the expression of a single marker and
that multiple immunoreactivities of several markers are instead
needed to identify cells fated to become OPCs.39 Furthermore,
in contrast to the A2B5-positive cells obtained from fetal
or adult brain tissues with deﬁned ages and localizations,
A2B5-positive cells obtained from hPSCs are not well
characterized in terms of developmental stage, cellular pheno-
type and fate. In fact, the A2B5-positive cells that ﬁrst emerged
at the neural rosette stage lacked PDGFRα and NG2 expression
(data not shown) and even retained the potential to generate
neurons and astrocytes when placed in spontaneous differen-
tiation conditions in vitro (Supplementary Figure 4), suggesting
that they were unlikely to be fully committed to forming OPCs.
Our endeavor to further commit their fate to the formation of
OPCs led to the discovery that the exposure of A2B5-positve
cells to signaling cues, including PDGF-AA, SHH and IGF-1,
robustly increases the number of cells positive for PDGFRα and
NG2 in the culture (Figure 1). The upregulated expression of
genes implicated in OD lineage speciﬁcation (that is, SOX8/10
and OLIG1/2) induced by the treatment strongly supports the
commitment of A2B5-positive cells to the OPC fate (Figure 1).
To date, evidence has been accumulating that PDGFRα-
positive and/or NG2-positive cells might represent populations
that contribute to the generation of ODs in the CNS.39
A previous report on the speciﬁc gene-expression proﬁle of
A2B5-positive populations obtained from human white
matter-progenitor cells showed enriched expression of
PDGFRα and NG2, suggesting that the co-expression of those
three markers can deﬁne OPCs.47 More recent results by
the same group suggested that cells positive for CD130a
(a PDGFRα ecto-domain) isolated from human fetal brain
Figure 3 Histochemical detection of myelination 8 weeks after
OPC-like cell transplantation in SCI rats. (a) A diagram showing the
locations at which the 1-mm-cord slice was dissected from the
spinal cord to count the myelinated axons: the lesion epicenter,
5 mm rostral to the lesion epicenter and 5 mm caudal to the lesion
epicenter. (b) Photomicrographs of coronal sections from individual
1 mm cord slices, stained with toluidine blue, in sham-operated
rats and SCI rats treated with OPC-like cell transplants or PBS
vehicle. Areas in the ventrolateral white matter were initially located
at ×40 magniﬁcation (insets in b(i)); images were then magniﬁed
up to ×400 and captured by a digital camera (b(ii)). A square
frame (50×50 μm2) randomly overlaid on the digital images was
magniﬁed for cell counting (b(iii)). (c) Histograms displaying the
mean number of myelinated axons in the squares sampled from the
ventrolateral white matter on both sides of the spinal cord over
each of 10 semi-thin sections obtained at each spinal cord
location in a given rat. The mean numbers of myelinated axons
were signiﬁcantly increased at all cord levels in the OPC-like
cell-transplanted SCI rats compared with the vehicle-treated SCI
rats, although these increased numbers were smaller than
the increased numbers of myelinated axons observed in the
sham-operated rats. Error bars indicate s.e.m. *Po0.05.
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tissue were mutually responsible for the myelinogenic
potential displayed by subpopulations of A2B5-positive cells.48
Another study showed that the transplantation of A2B5/NG2
double-positive cells isolated from human fetal tissue
signiﬁcantly improved the recovery of locomotor and sensory
function in an SCI rat model.49 These results collectively
support the idea that NPs with A2B5/PDGFRα/NG2 triple-
immunoreactivity might present the genuine features of OPCs
that ﬁrst emerge in human CNS development and thus serve as
a suitable source of cells to replace ODs lost due to SCI.
The OPC-like phenotypes within the A2B5-positive
population were acquired in a relatively short period of time
in our differentiation condition. This is probably because the
increased purity of the cell population makes the cells more
amenable to signaling cues that commit them to an OPC-like
fate. PDGF (particularly the PDGF-AA isoform) has been used
as a ‘common factor’ in previous studies for OD differentiation
from hPSCs39 due to its crucial role in the speciﬁcation of
OPCs in mammalian development.50,51 In addition, mouse
genetic studies have demonstrated that Shh is an essential
component of Olig1/2 expression, thereby inducing the
development of ODs.30,52 Those results were supported by
recent evidence that SHH treatment is required for OPC
speciﬁcation through the induction of OLIG2, NKX2.2 and
SOX10 in hESC-derived NPCs patterned to a caudal fate.53
IGF-1 was also shown to retain an instructive effect on neural
progenitors for OD differentiation by modulating BMP
signaling,31 which prompted multiple studies to employ
IGF-1 treatment in the differentiation of OPCs/ODs from
hPSCs.53,54 The combination of these three signaling cues
might be the main factor contributing to the fast speciﬁcation
of OPC lineages from pure populations of A2B5-positive
NPCs. Finally, the utility of ﬁbronectin as an extracellular
matrix component might facilitate the differentiation of NPCs
to OPC lineages, as it was reported that ﬁbronectin showed a
greater effect on the growth and differentiation of OPCs than
any of the other extracellular matrix components tested.55
Hence, we conclude that the combination of OPC-inducing
Figure 4 Cells derived from the OPC-like transplants in the injured spinal cord 8 weeks post transplantation. (a) A sagittal section image of
the spinal cord illustrating the lesion/transplant site, adjacent area and injury-induced lesion cavity (area within the dotted line) ﬁlled with
transplants. HNA-positive cells (green) survived and migrated both rostrally and caudally within the injury-induced cavity to distances of at
least 5 mm from the transplanted site. Although the majority of HNA-positive cells was located within 1.5–3 mm rostral and caudal to
the transplanted site, a larger proportion of cells migrated rostrally. (b) High-magniﬁcation images of the small area indicated by the
open-headed arrow in a. The survival of oligodendrocytes derived from the transplants was conﬁrmed by triple labeling with DAPI,
anti-HNA and anti-MBP antibodies (arrows in photo at the bottom right). (c–e) Coronal section image of the spinal cord, showing
other types of surviving cells derived from the transplants (arrows); (c) GFAP-positive cells (red), (d) MAP-positive cells (red) and
(e) Ki67-positive cells (red) that are proliferative.
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cues and appropriate extracellular matrix synergistically
contribute to the early differentiation of pure populations of
A2B5-positive cells to OPCs within a short period of time.
In addition to providing rapid differentiation to the desired
cell type, our method provides a cell source that does not
appear to lead to deleterious outcomes after transplantation,
such as tumor formation. The transplantation of hPSC-derived
neural cells retains the possibility of contamination by
undifferentiated or unwanted cells (for example, cells of a
non-neural lineage), especially in cases where cells that might
not be fully committed to a speciﬁc lineage are used for
transplantation.56 In this regard, we undertook efforts to
reduce the heterogeneity of the cells by (1) developing an
efﬁcient differentiation strategy to minimize unwanted cell
populations and (2) sorting the cells based on markers speciﬁc
to the cells of interest. Our previous results showed an absence
of meso-endodermal derivatives and undifferentiated remnants
after neural induction by the strong and simultaneous
inhibition of BMP and Activin/Nodal signals.36 Furthermore,
cell sorting based on a neural-speciﬁc marker excludes the
possibility of contamination by unwanted cells. The absence of
any abnormal tissues after cell transplantation strongly suggests
that the combination of those two paradigms makes our
method amenable to cell replacement therapy for SCI.
Although the data presented in our study support the
regenerative potential of OPC-like cells, one must be cautious
in interpreting the improvement of locomotor function
after cell transplantation to mean that the outcome is indeed
directly driven by remyelination of spared axons by OPC-like
transplants. In general, beneﬁts of stem/precursor-cell
transplantation include neuro-protective effects. Therefore,
we cannot exclude the possibility that an increased number
of myelinated axons in the spinal cords that received the cell
transplantation (Figure 3) resulted from paracrine effects of
the graft (that is, through secreting growth factors and
neurotrophic factors) to either protect the cells in the injury
site from massive cell death57 or to direct endogenous stem
cells to differentiate.58 This idea is widely supported by
numerous studies. For example, bFGF, which is known to be
secreted from hPSC-derived neural progenies injected in
animal brains,59 has been shown to have neuroprotective,
angiogenic and cavitation-reducing effects (reviewed in ref. 60).
In addition, recent evidence has shown that dormant
ependymal cells start dividing, migrating and giving rise to
oligodendrocytes after spinal cord injury61 and that the
co-administration of EGF and bFGF promoted the prolifera-
tion of ependymal cells in adult rat spinal cord.62 Thus, a
pleiotrophic factor such as bFGF might be one of several
paracrine factor candidates that induce further beneﬁcial effects
on locomotor function in addition to myelination following
OPC-like cell transplantation. There is also the possibility
that the increased number of myelinated axons and MBP
immunoreactivity around HNA-positive nuclei may originate
from Schwann cells, which are myelinating cells in the
peripheral nervous system, that are differentiated from
OPC-like cells (as in recent studies showing Schwann cell
differentiation from CNS glial stem cells63). Thus, in order to
deﬁne the exact role of OPC-like cell transplantation in injured
spinal cords, further assessment regarding grafted cell-fate
determination and the origin of myelinating cells may be
required.
Nevertheless, our results promptly contribute to overcoming
current limitations, including the lengthy procedure time
required to obtain transplantable OPCs. Although more
detailed developmental mechanisms underlying our in vitro
differentiation system and the role of OPC-like cells in
improvement of locomotor function in SCI require further
study, we believe that our current differentiation system
represents a signiﬁcant advancement toward obtaining a cell
source from hPSCs for a pre-clinical study of replacement
therapy for SCI.
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